CSL Limited's financial performance reveals not just growth but a commitment to future innovations. With a total revenue of $22.2 billion, the company allocated $1.43 billion—approximately 9.6% of its ...

It’s not Trump’s tariffs that could pressure the CSL share price, but a new high-level government appointee. Here’s why.

Are CSL shares likely to go up from here? The post Down 11% in 2025, are CSL shares a good buy right now? appeared first on ...

Cochin Shipyard Limited (CSL) is a Government of India enterprise concerned with shipbuilding and repair yards. Though its ...

Investors are in panic as Australian drug companies could be the next victims in an expansion of the US trade war.

UBS analyst Laura Sutcliffe maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$310.00. The company’s ...

Discover why CSL and WiseTech Global are emerging as potential buying opportunities despite recent market turbulence. Learn ...

Recent trading sessions have been turbulent for CSL Ltd, with shares declining sharply amid mounting concerns surrounding international trade policies. After a fall of 1.7% on Friday and a further ...

Defensive shares are a way to try and limit some of the bleeding in times of economic downturn. Is CSL a good option right ...

Australian biotech major CSL Limited (ASX: CSL) subsidiary CSL Behring today announced that it has successfully concluded ...

In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...